EFIM Announces New Partnership with AMBOSS

Submitted by Aneta on 14 August 2025 - 16:00

We are delighted to announce a new partnership between EFIM and AMBOSS, a leading medical knowledge platform known for its high-quality content, innovative technology, and commitment to meeting physicians’ needs.

AMBOSS is offering exclusive Benefits for EFIM-Member Societies
All EFIM ordinary and associate member societies will receive special, ongoing benefits for their members:

Eighth EMA-Medicines for Europe bilateral meeting, European Medicines Agency, Amsterdam, the Netherlands, from 9 September 2025, 15:00 (CEST) to 9 September 2025, 17:00 (CEST)

Submitted by Anonymous (not verified) on 14 August 2025 - 9:25

Eighth EMA-Medicines for Europe bilateral meeting, European Medicines Agency, Amsterdam, the Netherlands, from 9 September 2025, 15:00 (CEST) to 9 September 2025, 17:00 (CEST)

Human medicines European public assessment report (EPAR): Amvuttra, vutrisiran, Date of authorisation: 15/09/2022, Revision: 5, Status: Authorised

Submitted by Anonymous (not verified) on 13 August 2025 - 15:34

Human medicines European public assessment report (EPAR): Amvuttra, vutrisiran, Date of authorisation: 15/09/2022, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Exparel liposomal, bupivacaine, Date of authorisation: 16/11/2020, Revision: 2, Status: Authorised

Submitted by Anonymous (not verified) on 13 August 2025 - 14:41

Human medicines European public assessment report (EPAR): Exparel liposomal, bupivacaine, Date of authorisation: 16/11/2020, Revision: 2, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More